ArticleSouth Asian journal of cancer2014
Evaluation of protective effect of myricetin, a bioflavonoid in dimethyl benzanthracene-induced breast cancer in female Wistar rats.
Article in South Asian journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 45 citations in OpenAlex.
- Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts.Frontiers in oncology · 2025Article
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways.International journal of molecular sciences · 2023Review
- Exploring the interaction of myricetin with human alpha-2-macroglobulin: biophysical and in-silico analysis.Journal of biological physics · 2023Article
- Biopolymeric nanoparticles based effective delivery of bioactive compounds toward the sustainable development of anticancerous therapeutics.Frontiers in nutrition · 2022Review
- Prophylactic effect of myricetin and apigenin against lipopolysaccharide-induced acute liver injury.Molecular biology reports · 2021Article
- Human Papillomavirus 16-Transgenic Mice as a Model to Study Cancer-Associated Cachexia.International journal of molecular sciences · 2020Article
- Protective Effects of Myricetin on Benzo[a]pyrene-Induced 8-Hydroxy-2'-Deoxyguanosine and BPDE-DNA Adduct.Antioxidants (Basel, Switzerland) · 2020Article
- Effect of myricetin on the gene expressions of NOX3, TGF-β1, prestin, and HSP-70 and anti-oxidant activity in the cochlea of noise-exposed rats.Iranian journal of basic medical sciences · 2020Article
- Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-International journal of molecular sciences · 2020Article
- Bioactive Compounds: Natural Defense Against Cancer?Biomolecules · 2019Review
- Electro-Acupuncture Therapy Increases Serum Interferon-γ Levels in Rats with 7, 12 Dimethylbenz(α)anthracene (DMBA)-Induced Breast TumorsAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.Seminars in cancer biology · 2016Review
- Mobilization of Copper ions by Flavonoids in Human Peripheral Lymphocytes Leads to Oxidative DNA Breakage: A Structure Activity Study.International journal of molecular sciences · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most common cancers worldwide. Alarmingly, the incidence of breast cancer is rising rapidly in India.
aimThe present research was focused to assess the role of myricetin; a bioflavonoid in 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer in female Wistar rats. MATERIALS AND
methodsA total of 36 female Wistar rats (total 6 groups, n = 6 per group) 6 - 8 weeks old, weighing 150 gm were used in the study. DMBA was given at the dose of 7.5 mg/kg subcutaneously in the mammary region once a week for 4 consecutive weeks in group 2. Vincristine was given in the dose of 500 μg/kg intraperitonially every week for 4 consecutive weeks in group 3. Myricetin was given orally in a dose of 50, 100, and 200 mg/kg in group 4, 5, and 6 respectively. The statistical significance of the data was determined using one way analysis of variance and Duncan's multiple range test.
resultsThe result showed that myricetin increased the antioxidant levels in plasma, erythrocyte lysate, and breast tissue and was effective in preventing the oxidative damage induced by the carcinogen DMBA. Myricetin 50, 100, and 200 mg/kg/oral for 120 days treated animal resulted comparable results to that of standard vincristine and control groups.
conclusionsMyricetin was found to be either equieffective or more effective than vincristine in all the parameters studied. Myricetin proved the capacity of flavonols to act as antioxidant in cells represents a potential treatment in the field of oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.